ST Renfu announced that its holding subsidiary Yichang Renfu RFUS-188 injection recently entered a phase II clinical trial study for the treatment of acute pain. Recently, Yichang's fumidazolam injection obtained marketing approval from the UK Medicines and Health Products Administration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.